FDA seeks comments on ways to facilitate appropriate opioid prescribing
The Food and Drug Administration seeks stakeholder input on how it might use Risk Evaluation and Mitigation Strategies to facilitate appropriate prescribing of opioid pain relievers. For example, the agency’s Opioid Policy Steering Committee is considering using REMS to require sponsors to ensure that opioid analgesic prescriptions exceeding a certain amount document medical necessity and/or leverage a nationwide prescription history database to prevent misuse or abuse, the FDA notice states. The agency will hold a Jan. 30 public hearing on the issue, with comments accepted through March 16.
Related News Articles
Headline
The Centers for Medicare & Medicaid Services Aug. 1 issued a final rule for the inpatient psychiatric facility prospective payment system for fiscal year…
Headline
The Centers for Medicare & Medicaid Services Aug. 1 released the fiscal year 2026 final rule for inpatient rehabilitation facilities. The rule will…
Headline
The Food and Drug Administration July 31 announced that it is requiring safety label changes to all opioid pain medications to further emphasize and explain…
Headline
The Senate Appropriations Committee July 31 advanced the fiscal year 2026 appropriations bill for the Departments of Labor, Health and Human Services,…
Headline
The Trump administration July 31 announced modified reciprocal tariffs for several nations that would begin Aug. 7, updating those previously announced in…
Perspective
House members are back in their districts for the August recess and senators are likely to return to their states soon.While lawmakers are home, it’s important…